{"id":"https://openalex.org/W2978029751","doi":"https://doi.org/10.1158/2159-8290.cd-19-0367","title":"Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma","display_name":"Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma","alternate_titles":[],"publication_year":2019,"publication_date":"2019-12-01","ids":{"openalex":"https://openalex.org/W2978029751","doi":"https://doi.org/10.1158/2159-8290.cd-19-0367","mag":"2978029751","pmid":"https://pubmed.ncbi.nlm.nih.gov/31575540"},"language":"en","primary_location":{"id":"doi:10.1158/2159-8290.cd-19-0367","doi":"https://doi.org/10.1158/2159-8290.cd-19-0367","is_oa":false,"landing_page_url":"https://doi.org/10.1158/2159-8290.cd-19-0367","pdf_url":null,"source":{"id":"https://openalex.org/S2486275289","display_name":"Cancer Discovery","issn_l":"2159-8274","issn":["2159-8274","2159-8290"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Discovery","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2978029751"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029182005","display_name":"Megan A. Hatlen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Megan A. Hatlen","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065462815","display_name":"Oleg Schmidt\u2010Kittler","orcid":"https://orcid.org/0009-0000-6800-8920","observed_orcids":["https://orcid.org/0009-0000-6800-8920","https://orcid.org/0000-0003-1501-4985"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Oleg Schmidt-Kittler","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024845646","display_name":"Cori Ann Sherwin","orcid":"https://orcid.org/0009-0008-8818-4567","observed_orcids":["https://orcid.org/0009-0008-8818-4567"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Cori Ann Sherwin","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076607552","display_name":"Emily Rozsahegyi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Emily Rozsahegyi","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072574706","display_name":"Nooreen T. Rubin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nooreen Rubin","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062122842","display_name":"Michael P. Sheets","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael P. Sheets","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005920640","display_name":"Joseph L. Kim","orcid":"https://orcid.org/0000-0002-7739-2343","observed_orcids":["https://orcid.org/0000-0002-7739-2343"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Joseph L. Kim","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":"https://orcid.org/0000-0002-7739-2343","affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071280995","display_name":"Chandrasekhar V. Miduturu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Chandrasekhar Miduturu","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089979299","display_name":"Neil Bifulco","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Neil Bifulco","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010156999","display_name":"Natasja Brooijmans","orcid":"https://orcid.org/0000-0003-3514-4189","observed_orcids":["https://orcid.org/0000-0003-3514-4189"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Natasja Brooijmans","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034389447","display_name":"Hongliang Shi","orcid":"https://orcid.org/0000-0001-9666-1927","observed_orcids":["https://orcid.org/0000-0001-9666-1927"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hongliang Shi","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054293469","display_name":"Timothy J. Guzi","orcid":"https://orcid.org/0000-0002-2620-6897","observed_orcids":["https://orcid.org/0000-0002-2620-6897"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Timothy Guzi","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048943840","display_name":"Andy Boral","orcid":"https://orcid.org/0000-0001-6702-630X","observed_orcids":["https://orcid.org/0000-0001-6702-630X"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andy Boral","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020235332","display_name":"Christoph Lengauer","orcid":"https://orcid.org/0000-0002-4498-7228","observed_orcids":["https://orcid.org/0000-0002-4498-7228"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Christoph Lengauer","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017360327","display_name":"Marion Dorsch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Marion Dorsch","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045482037","display_name":"Richard D. Kim","orcid":"https://orcid.org/0000-0002-8448-844X","observed_orcids":["https://orcid.org/0000-0002-8448-844X"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Richard D. Kim","raw_affiliation_strings":["2H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"],"raw_orcid":"https://orcid.org/0000-0002-7739-2343","affiliations":[{"raw_affiliation_string":"2H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005925636","display_name":"Yoon\u2010Koo Kang","orcid":"https://orcid.org/0000-0003-0783-6583","observed_orcids":["https://orcid.org/0000-0003-0783-6583"]},"institutions":[{"id":"https://openalex.org/I2801680663","display_name":"Asan Medical Center","ror":"https://ror.org/03s5q0090","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I2801680663","https://openalex.org/I4210167194"]},{"id":"https://openalex.org/I40542001","display_name":"University of Ulsan","ror":"https://ror.org/02c2f8975","country_code":"KR","type":"education","lineage":["https://openalex.org/I40542001"]}],"countries":["KR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yoon-Koo Kang","raw_affiliation_strings":["3Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea","institution_ids":["https://openalex.org/I2801680663","https://openalex.org/I40542001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061909254","display_name":"Beni B. Wolf","orcid":"https://orcid.org/0009-0008-3809-4280","observed_orcids":["https://orcid.org/0009-0008-3809-4280"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Beni B. Wolf","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5010844468","display_name":"Klaus P. Hoeflich","orcid":"https://orcid.org/0009-0008-8801-2765","observed_orcids":["https://orcid.org/0009-0008-8801-2765"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Klaus P. Hoeflich","raw_affiliation_strings":["1Blueprint Medicines Corporation, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines Corporation, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210100156"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.7449,"has_fulltext":false,"cited_by_count":121,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.95263287,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"9","issue":"12","first_page":"1686","last_page":"1695"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":0.006500000134110451,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hepatocellular-carcinoma","display_name":"hepatocellular carcinoma","score":0.9700000286102295},{"id":"https://openalex.org/keywords/fgfr4","display_name":"FGFR4","score":0.9990000128746033},{"id":"https://openalex.org/keywords/fgf19","display_name":"FGF19","score":0.9110000133514404},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.8090000152587891},{"id":"https://openalex.org/keywords/gatekeeper-mutations","display_name":"gatekeeper mutation","score":0.9079999923706055},{"id":"https://openalex.org/keywords/oncogenic-drivers","display_name":"oncogenic drivers","score":0.7639999985694885},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.6000000238418579},{"id":"https://openalex.org/keywords/pan-fgfr-inhibitor","display_name":"pan-FGFR inhibitor","score":0.8510000109672546}],"concepts":[{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.9013164043426514},{"id":"https://openalex.org/C57473165","wikidata":"https://www.wikidata.org/wiki/Q7315604","display_name":"Resistance (ecology)","level":2,"score":0.5286937952041626},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.47333794832229614},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4106413424015045},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.377002477645874},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.34837448596954346},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.3472033143043518},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3359973728656769},{"id":"https://openalex.org/C18903297","wikidata":"https://www.wikidata.org/wiki/Q7150","display_name":"Ecology","level":1,"score":0.052394360303878784}],"mesh":[{"descriptor_ui":"D000072417","descriptor_name":"Protein Domains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005346","descriptor_name":"Fibroblast Growth Factors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006528","descriptor_name":"Carcinoma, Hepatocellular","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":true},{"descriptor_ui":"D006528","descriptor_name":"Carcinoma, Hepatocellular","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006528","descriptor_name":"Carcinoma, Hepatocellular","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D006528","descriptor_name":"Carcinoma, Hepatocellular","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":true},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008958","descriptor_name":"Models, Molecular","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009368","descriptor_name":"Neoplasm Transplantation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011714","descriptor_name":"Pyrans","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D015972","descriptor_name":"Gene Expression Regulation, Neoplastic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051499","descriptor_name":"Receptor, Fibroblast Growth Factor, Type 4","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D051499","descriptor_name":"Receptor, Fibroblast Growth Factor, Type 4","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051499","descriptor_name":"Receptor, Fibroblast Growth Factor, Type 4","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/2159-8290.cd-19-0367","doi":"https://doi.org/10.1158/2159-8290.cd-19-0367","is_oa":false,"landing_page_url":"https://doi.org/10.1158/2159-8290.cd-19-0367","pdf_url":null,"source":{"id":"https://openalex.org/S2486275289","display_name":"Cancer Discovery","issn_l":"2159-8274","issn":["2159-8274","2159-8290"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Discovery","raw_type":"journal-article"},{"id":"pmid:31575540","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31575540","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer discovery","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W1566932673","https://openalex.org/W1971837077","https://openalex.org/W1979702889","https://openalex.org/W1996958662","https://openalex.org/W2034198983","https://openalex.org/W2041451676","https://openalex.org/W2042619042","https://openalex.org/W2066277837","https://openalex.org/W2095943598","https://openalex.org/W2100772783","https://openalex.org/W2130787560","https://openalex.org/W2143204311","https://openalex.org/W2150717198","https://openalex.org/W2560499218","https://openalex.org/W2565125121","https://openalex.org/W2606367731","https://openalex.org/W2606928616","https://openalex.org/W2787358630","https://openalex.org/W2793610958","https://openalex.org/W2803626382","https://openalex.org/W2809889937","https://openalex.org/W2892481732","https://openalex.org/W2917837889","https://openalex.org/W2945968242","https://openalex.org/W2977600124","https://openalex.org/W3139763557"],"related_works":["https://openalex.org/W2993740971","https://openalex.org/W2994511758","https://openalex.org/W2948685669","https://openalex.org/W6958993321","https://openalex.org/W4386757379","https://openalex.org/W2885736997","https://openalex.org/W4307906449","https://openalex.org/W2968913253","https://openalex.org/W4200242790","https://openalex.org/W2977600124"],"abstract_inverted_index":{"Hepatocellular":[0],"carcinoma":[1],"(HCC)":[2],"is":[3,40,139,197],"a":[4,41,150],"leading":[5],"cause":[6],"of":[7,29,46,76,109,130,152,174,182],"cancer":[8,31],"mortality":[9],"worldwide":[10],"with":[11,57,59,85],"no":[12],"clinically":[13],"confirmed":[14,89],"oncogenic":[15,123,167],"driver.":[16,168],"Although":[17],"preclinical":[18],"studies":[19],"implicate":[20],"the":[21,27,67,73,107,134,140,180,200],"FGF19":[22,61],"receptor":[23],"FGFR4":[24,33,47,77,120,145],"in":[25,55,66,72,81,93,96,106,133,176,199],"hepatocarcinogenesis,":[26],"dependence":[28],"human":[30],"on":[32],"has":[34],"not":[35],"been":[36],"demonstrated.":[37],"Fisogatinib":[38],"(BLU-554)":[39],"potent":[42],"and":[43,48,52,69,95,125,178,191],"selective":[44],"inhibitor":[45,101],"demonstrates":[49],"clinical":[50,154],"benefit":[51],"tumor":[53],"regression":[54],"patients":[56,83],"HCC":[58,103,177],"aberrant":[60],"expression.":[62],"Mutations":[63],"were":[64,88],"identified":[65],"gatekeeper":[68],"hinge-1":[70],"residues":[71],"kinase":[74,132,146],"domain":[75,147],"upon":[78],"disease":[79],"progression":[80],"2":[82],"treated":[84],"fisogatinib,":[86],"which":[87],"to":[90,142,156],"mediate":[91],"resistance":[92,155],"vitro":[94],"vivo.":[97],"A":[98],"gatekeeper-agnostic,":[99],"pan-FGFR":[100],"decreased":[102],"xenograft":[104],"growth":[105],"presence":[108],"these":[110],"mutations,":[111],"demonstrating":[112],"continued":[113],"FGF19\u2013FGFR4":[114,162],"pathway":[115,163],"dependence.":[116],"These":[117,169],"results":[118],"validate":[119],"as":[121,149,165],"an":[122,166],"driver":[124],"warrant":[126],"further":[127,160,172],"therapeutic":[128],"targeting":[129],"this":[131],"clinic.":[135],"Significance:":[136],"Our":[137],"study":[138],"first":[141],"demonstrate":[143],"on-target":[144],"mutations":[148],"mechanism":[151],"acquired":[153],"targeted":[157],"therapy.":[158],"This":[159,195,202],"establishes":[161],"activation":[164],"findings":[170],"support":[171],"investigation":[173],"fisogatinib":[175],"inform":[179],"profile":[181],"potential":[183],"next-generation":[184],"inhibitors.":[185],"See":[186],"related":[187],"commentary":[188],"by":[189],"Subbiah":[190],"Pal,":[192],"p.":[193,205],"1646.":[194],"article":[196],"highlighted":[198],"In":[201],"Issue":[203],"feature,":[204],"1631":[206]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2978029751","counts_by_year":[{"year":2026,"cited_by_count":14},{"year":2025,"cited_by_count":19},{"year":2024,"cited_by_count":17},{"year":2023,"cited_by_count":14},{"year":2022,"cited_by_count":21},{"year":2021,"cited_by_count":21},{"year":2020,"cited_by_count":10},{"year":2019,"cited_by_count":5}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2019-10-10T00:00:00"}
